AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today the launch of its new miRNA Biofluids service offering designed to interrogate miRNAs from serum, plasma, cerebral spinal fluid, and urine. Supported by a growing body of literature, the utility of miRNA biomarkers in biofluids has been demonstrated for numerous disease areas including Cancer, Neurology, Autoimmune, and Cardiovascular diseases. Over the past 5 years, Asuragen scientists have developed a suite of optimized protocols, now available as services, for the isolation and analysis of miRNAs from diverse biofluids. The ability to perform biomarker analysis from easily accessible and regenerative biofluid samples, in contrast to procuring invasive tissue biopsies, greatly facilitates sample collection and patient recruitment for clinical studies.
